Literature DB >> 19804796

kappa-Opioid receptor signaling and brain reward function.

Adrie W Bruijnzeel1.   

Abstract

The dynorphin-like peptides have profound effects on the state of the brain reward system and human and animal behavior. The dynorphin-like peptides affect locomotor activity, food intake, sexual behavior, anxiety-like behavior, and drug intake. Stimulation of kappa-opioid receptors, the endogenous receptor for the dynorphin-like peptides, inhibits dopamine release in the striatum (nucleus accumbens and caudate putamen) and induces a negative mood state in humans and animals. The administration of drugs of abuse increases the release of dopamine in the striatum and mediates the concomitant release of dynorphin-like peptides in this brain region. The reviewed studies suggest that chronic drug intake leads to an upregulation of the brain dynorphin system in the striatum and in particular in the dorsal part of the striatum/caudate putamen. This might inhibit drug-induced dopamine release and provide protection against the neurotoxic effects of high dopamine levels. After the discontinuation of chronic drug intake these neuroadaptations remain unopposed which has been suggested to contribute to the negative emotional state associated with drug withdrawal and increased drug intake. kappa-Opioid receptor agonists have also been shown to inhibit calcium channels. Calcium channel inhibitors have antidepressant-like effects and inhibit the release of norepinephrine. This might explain that in some studies kappa-opioid receptor agonists attenuate nicotine and opioid withdrawal symptomatology. A better understanding of the role of dynorphins in the regulation of brain reward function might contribute to the development of novel treatments for mood disorders and other disorders that stem from a dysregulation of the brain reward system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804796      PMCID: PMC2787673          DOI: 10.1016/j.brainresrev.2009.09.008

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  260 in total

1.  The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice.

Authors:  M Tsuji; H Takeda; T Matsumiya; H Nagase; M Narita; T Suzuki
Journal:  Life Sci       Date:  2001-03-02       Impact factor: 5.037

2.  Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents.

Authors:  John F Cryan; Daniel Hoyer; Athina Markou
Journal:  Biol Psychiatry       Date:  2003-07-01       Impact factor: 13.382

3.  Dopamine D1 and D2 receptor agonists induce opposite changes in the firing rate of ventral pallidal neurons.

Authors:  R J Maslowski; T C Napier
Journal:  Eur J Pharmacol       Date:  1991-07-23       Impact factor: 4.432

4.  Pharmacological regulation of striatal prodynorphin peptides.

Authors:  K A Trujillo; H Akil
Journal:  Prog Clin Biol Res       Date:  1990

5.  Kappa opioid inhibition of morphine and cocaine self-administration in rats.

Authors:  S D Glick; I M Maisonneuve; J Raucci; S Archer
Journal:  Brain Res       Date:  1995-05-29       Impact factor: 3.252

6.  Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine.

Authors:  L H Parsons; A D Smith; J B Justice
Journal:  Synapse       Date:  1991-09       Impact factor: 2.562

Review 7.  A role for brain stress systems in addiction.

Authors:  George F Koob
Journal:  Neuron       Date:  2008-07-10       Impact factor: 17.173

8.  Phencyclidine (angel dust)/sigma "opiate" receptor: visualization by tritium-sensitive film.

Authors:  R Quirion; R P Hammer; M Herkenham; C B Pert
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

Review 9.  Limbic-striatal interactions in reward-related processes.

Authors:  T W Robbins; M Cador; J R Taylor; B J Everitt
Journal:  Neurosci Biobehav Rev       Date:  1989 Summer-Fall       Impact factor: 8.989

10.  Neuroleptic-induced "anhedonia" in rats: pimozide blocks reward quality of food.

Authors:  R A Wise; J Spindler; H deWit; G J Gerberg
Journal:  Science       Date:  1978-07-21       Impact factor: 47.728

View more
  94 in total

1.  The role of endogenous dynorphin in ethanol-induced state-dependent CPP.

Authors:  Khanh Nguyen; Andy Tseng; Paul Marquez; Abdul Hamid; Kabirullah Lutfy
Journal:  Behav Brain Res       Date:  2011-10-29       Impact factor: 3.332

Review 2.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

Review 3.  The role of kappa-opioid receptor activation in mediating antinociception and addiction.

Authors:  Yu-hua Wang; Jian-feng Sun; Yi-min Tao; Zhi-qiang Chi; Jing-gen Liu
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 4.  Dynorphin A analogs for the treatment of chronic neuropathic pain.

Authors:  Sara M Hall; Yeon Sun Lee; Victor J Hruby
Journal:  Future Med Chem       Date:  2016-01-29       Impact factor: 3.808

5.  Who Receives Nalmefene and How Does It Work in the Real World? A Single-Arm, Phase IV Study of Nalmefene in Alcohol Dependent Outpatients: Baseline and 1-Month Results.

Authors:  Pablo Barrio; Lluisa Ortega; Josep Guardia; Carlos Roncero; Lara Yuguero; Antoni Gual
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

Review 6.  Neurobiology of aversive states.

Authors:  Erin N Umberg; Emmanuel N Pothos
Journal:  Physiol Behav       Date:  2011-05-01

7.  Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats.

Authors:  E Andrew Townsend; Jennifer E Naylor; S Stevens Negus; Shelley R Edwards; Hina N Qureshi; Hunter W McLendon; Christopher R McCurdy; Coco N Kapanda; Jussara M do Carmo; Fernanda S da Silva; John E Hall; Kenneth J Sufka; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2017-05-31       Impact factor: 4.530

Review 8.  Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.

Authors:  William A Carlezon; Andrew D Krystal
Journal:  Depress Anxiety       Date:  2016-10       Impact factor: 6.505

9.  Effects of oxycodone on brain responses to emotional images.

Authors:  Margaret C Wardle; Daniel A Fitzgerald; Michael Angstadt; Christine A Rabinak; Harriet de Wit; K Luan Phan
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

10.  Synthetic and Receptor Signaling Explorations of the Mitragyna Alkaloids: Mitragynine as an Atypical Molecular Framework for Opioid Receptor Modulators.

Authors:  Andrew C Kruegel; Madalee M Gassaway; Abhijeet Kapoor; András Váradi; Susruta Majumdar; Marta Filizola; Jonathan A Javitch; Dalibor Sames
Journal:  J Am Chem Soc       Date:  2016-05-18       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.